LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other research firms also recently issued reports on LMAT. Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Finally, JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Down 1.3 %

Shares of LMAT stock opened at $101.12 on Thursday. The company has a 50 day moving average price of $96.82 and a 200-day moving average price of $88.78. LeMaitre Vascular has a 52 week low of $52.72 and a 52 week high of $109.58. The firm has a market capitalization of $2.27 billion, a PE ratio of 55.26, a P/E/G ratio of 2.57 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. Analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several large investors have recently made changes to their positions in LMAT. Conestoga Capital Advisors LLC increased its position in LeMaitre Vascular by 1.9% in the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Copeland Capital Management LLC grew its stake in shares of LeMaitre Vascular by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares in the last quarter. State Street Corp increased its holdings in shares of LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock worth $76,363,000 after buying an additional 28,525 shares during the last quarter. Congress Asset Management Co. raised its position in shares of LeMaitre Vascular by 2.6% during the 3rd quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after buying an additional 18,295 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of LeMaitre Vascular by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after acquiring an additional 23,443 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.